HURA - TuHURA Biosciences, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.54 0.02 (0.79%)	---	---	---	0.04 (1.54%)	0.01 (0.39%)	0.0 (0.0%)	0.0 (0.0%)

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed